<DOC>
	<DOCNO>NCT01019161</DOCNO>
	<brief_summary>The purpose study assess AZD1152 absorb excrete body patient Acute Myeloid Leukaemia ( AML ) .</brief_summary>
	<brief_title>An Open Label , Single Centre Mass Balance C14 Study Patients With Acute Myeloid Leukaemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients relapse refractory AML standard therapy anticipate result durable remission . Or , patient newly diagnose AML consider suitable standard induction consolidation chemotherapy Ability stay hospital 9 day [ 14C ] AZD1152 treatment cycle . Subjects relapse &gt; 1 year follow myeloablative therapy allogeneic bone marrow stem cell transplantation may eligible limited evidence extensive graftversushost disease QTc interval â‰¥470 m calculate single ECG reading mean 3 ECG reading use Fridericia 's Bazett 's correction Administration hydroxyurea control peripheral blood count prohibit within 24 hour prior first dose study drug Any chemotherapy radiotherapy within 14 day prior start study ( include palliative radiotherapy focal site )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Acute Myeloid Leukaemia ( AML )</keyword>
	<keyword>AML</keyword>
	<keyword>AZD1152</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>